Broadly protective Shigella vaccine based on type III secretion apparatus proteins.
about
The Many Faces of IpaBVaccines for the prevention of diarrhea due to cholera, shigella, ETEC and rotavirusManagement strategies in the treatment of neonatal and pediatric gastroenteritisThe non-flagellar type III secretion system evolved from the bacterial flagellum and diversified into host-cell adapted systemsA novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models.Virulence factors associated with pediatric shigellosis in Brazilian Amazon.Shigella: A Highly Virulent and Elusive PathogenShigella isolates from the global enteric multicenter study inform vaccine development.Influence of oligomerization state on the structural properties of invasion plasmid antigen B from Shigella flexneri in the presence and absence of phospholipid membranes.Immunogenic and invasive properties of Brucella melitensis 16M outer membrane protein vaccine candidates identified via a reverse vaccinology approachImpact of detergent on biophysical properties and immune response of the IpaDB fusion protein, a candidate subunit vaccine against Shigella species.Shigella outer membrane protein PSSP-1 is broadly protective against Shigella infection.The genome of Shigella dysenteriae strain Sd1617 comparison to representative strains in evaluating pathogenesis.Production of a Shigella sonnei Vaccine Based on Generalized Modules for Membrane Antigens (GMMA), 1790GAHBShigella IpaB and IpaD displayed on L. lactis bacterium-like particles induce protective immunity in adult and infant mice.Co-administration of rIpaB domain of Shigella with rGroEL of S. Typhi enhances the immune responses and protective efficacy against Shigella infection.Expression of Shigella flexneri ipaB Gene in Tobacco.Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD.Progress and pitfalls in Shigella vaccine research.Characterization of a novel fusion protein from IpaB and IpaD of Shigella spp. and its potential as a pan-Shigella vaccine.Functional and Antigen-Specific Serum Antibody Levels as Correlates of Protection against Shigellosis in a Controlled Human Challenge Study.Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine.An update on vaccines against Shigella.Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypesChlamydial Type III Secretion System Needle Protein Induces Protective Immunity against Chlamydia muridarum Intravaginal Infection.Recent progress towards development of a Shigella vaccine.Comparison of resistance to third-generation cephalosporins in Shigella between Europe-America and Asia-Africa from 1998 to 2012.Pathogen manipulation of B cells: the best defence is a good offence.The genomic signatures of Shigella evolution, adaptation and geographical spread.Detergent Isolation Stabilizes and Activates the Shigella Type III Secretion System Translocator Protein IpaC.Biophysical characterization of the type III secretion tip proteins and the tip proteins attached to bacterium-like particles.Type III Secretion in the Melioidosis Pathogen Burkholderia pseudomallei.Quantitative proteomic analysis of Burkholderia pseudomallei Bsa type III secretion system effectors using hypersecreting mutants.An attenuated Shigella mutant lacking the RNA-binding protein Hfq provides cross-protection against Shigella strains of broad serotype.Oligomeric states of the Shigella translocator protein IpaB provide structural insights into formation of the type III secretion translocon.Studies of the conformational stability of invasion plasmid antigen B from Shigella.Binding affects the tertiary and quaternary structures of the Shigella translocator protein IpaB and its chaperone IpgC.Ultrastructural analysis of IpaD at the tip of the nascent MxiH type III secretion apparatus of Shigella flexneriKinetic analysis and evaluation of the mechanisms involved in the resolution of experimental nontypeable Haemophilus influenzae-induced otitis media after transcutaneous immunization.Characterization and protective efficacy of type three secretion proteins as a broadly protective subunit vaccine against Salmonella enterica serovars.
P2860
Q26767237-F26F24C6-2A21-4FDF-89C9-FA80D44369D6Q26995690-6B6D902F-A842-4339-BEF5-0895AA05D9DEQ27004496-64341CCB-BA6D-4619-9553-EA73C6A4ADE3Q28276177-8D4C33DE-DF6B-4386-A611-CE54CB01915FQ30408273-C1E5E06C-CE15-4A11-91F7-5927EEB184FFQ33608925-A5CFAD73-BDDE-4166-8713-3DFC6A82A24AQ34019305-E5FBB1F6-675B-4197-81DA-DCF2A3C73EC0Q34202171-9C995EE2-FA0E-4FA9-98EE-1C8BE7CE9F37Q34389407-7B0E47B1-22C9-485D-B9AE-694C5AC33005Q34637943-12F344CE-5E92-49D9-A03B-C06887459E7AQ34889587-44B863E1-70F2-4BDB-942F-EE68DA7C534AQ35221181-63FEF116-A96B-4FEB-BE95-56256AB0CE8CQ35651224-B13677E7-D9F9-4EC8-ADDC-93C15F8F4165Q35924773-A186A698-8855-4757-8C6A-B10E5F545B32Q35946462-C6794E10-44B7-4454-8CA3-43393971AFA4Q36473218-FBEBC29F-E3FA-499D-BC10-4974BBBD83DDQ36946812-45515FC2-5001-4391-A319-C24164D8DC01Q37032264-EC62FB26-0C21-456B-8D75-14BA910B49AFQ37105553-94007EF3-FE2C-4A32-8A78-C876614ACA1DQ37335984-70EDB5AC-CBEC-4373-AF07-F96F549C1D72Q37633069-4B2DE8B2-E6DE-4932-B5BF-6342CF22482AQ37643320-D9AE5B9F-03B6-4316-B2E2-055272D182B2Q37668395-2D50A8F3-2B8B-4D6B-BA84-CFC35FE68CE0Q37720658-EFD8FA92-6702-4FC5-8ECC-5AF6EB1117C8Q37742680-520CDA5A-28A1-4C21-84E9-449060BABFC4Q38068954-DDE2B99D-D614-4C42-A8BB-DA99189D5A8AQ38305664-D3642B0B-B712-4E5B-BE74-243D622C2692Q38346756-6932E117-A579-4256-8ECE-DA1559E8A843Q38753453-240DDEAB-BA3A-45D0-A29A-13E372E1471FQ38853686-3A454F1E-20B6-4D92-B017-F578DFF96B3FQ39177635-012E0F44-9264-44AC-AEAA-B6E83043AE00Q39406159-55B1E7B9-6412-4B2F-9026-68A4C0CF08A0Q39407784-A22076F4-DB7D-486E-96BF-494B130C85B6Q40126474-D3E7CA06-BDBF-4AF0-9DC9-BEF49F251B11Q40564027-D7CE966C-409A-4C96-8DA6-12DBF955D473Q40564184-F0E66C09-1BA5-4567-8C5D-8CB911EA178FQ41893547-5F2DC83B-5230-4EF3-A696-8D6310D65885Q42183752-11332A6F-D083-4796-BAD9-FA68DE725DE4Q43243181-92E9F643-4DE7-49DD-A56D-E2C9ED0B2BE6Q47223049-48529837-D0AD-4F21-8BE0-F34111054C52
P2860
Broadly protective Shigella vaccine based on type III secretion apparatus proteins.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Broadly protective Shigella vaccine based on type III secretion apparatus proteins.
@ast
Broadly protective Shigella vaccine based on type III secretion apparatus proteins.
@en
type
label
Broadly protective Shigella vaccine based on type III secretion apparatus proteins.
@ast
Broadly protective Shigella vaccine based on type III secretion apparatus proteins.
@en
altLabel
Broadly protective Shigella vaccine based on type III secretion apparatus proteins
@en
prefLabel
Broadly protective Shigella vaccine based on type III secretion apparatus proteins.
@ast
Broadly protective Shigella vaccine based on type III secretion apparatus proteins.
@en
P2093
P2860
P921
P356
P1476
Broadly protective Shigella vaccine based on type III secretion apparatus proteins.
@en
P2093
Amy M Quick
Francisco J Martinez-Becerra
Gabriela Mellado-Sanchez
John D Clements
Jovita Diaz-McNair
Julian M Kissmann
Marcela F Pasetti
Shyamal P Choudhari
Wendy L Picking
P2860
P304
P356
10.1128/IAI.06174-11
P407
P577
2011-12-27T00:00:00Z